tiprankstipranks
Trending News
More News >
Laurus Labs Ltd. (IN:LAURUSLABS)
:LAURUSLABS
India Market
Advertisement

Laurus Labs Ltd. (LAURUSLABS) AI Stock Analysis

Compare
10 Followers

Top Page

IN:LAURUSLABS

Laurus Labs Ltd.

(LAURUSLABS)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
₹1,034.00
▲(6.60% Upside)
Laurus Labs' overall stock score is driven by strong technical momentum, despite overbought signals, and solid financial performance with revenue growth. However, high valuation metrics and cash flow challenges weigh on the score.

Laurus Labs Ltd. (LAURUSLABS) vs. iShares MSCI India ETF (INDA)

Laurus Labs Ltd. Business Overview & Revenue Model

Company DescriptionLaurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
How the Company Makes MoneyLaurus Labs generates revenue through multiple streams, primarily from the sale of active pharmaceutical ingredients (APIs) and finished formulations. The company has a robust client base that includes major pharmaceutical companies globally, which contributes significantly to its revenue through long-term supply agreements. Additionally, Laurus Labs engages in contract manufacturing services, allowing it to produce products for other pharmaceutical firms, thus diversifying its income sources. The company also invests in research and development to innovate and expand its product offerings, which can lead to new revenue opportunities. Strategic partnerships with other biotech and pharmaceutical companies further enhance its market reach and profitability. The combination of these factors, along with a focus on exports to regulated markets, plays a crucial role in Laurus Labs' financial performance.

Laurus Labs Ltd. Financial Statement Overview

Summary
Laurus Labs exhibits strong revenue growth and efficient cost management, but profitability margins are under pressure. The balance sheet shows moderate leverage with increasing liabilities, and cash flow challenges due to high capital expenditures need addressing to ensure liquidity stability.
Income Statement
72
Positive
Laurus Labs has shown consistent revenue growth, with a notable increase from 2024 to 2025. The gross profit margin remains strong, indicating effective cost management. However, the net profit margin has decreased due to rising expenses, impacting overall profitability.
Balance Sheet
65
Positive
The company maintains a balanced debt-to-equity ratio, reflecting moderate leverage. However, the equity ratio shows a declining trend, indicating increased liabilities relative to assets. Return on equity has weakened, reflecting a dip in profitability.
Cash Flow
58
Neutral
Operating cash flow has remained relatively stable, but free cash flow is negative due to high capital expenditures. The free cash flow to net income ratio indicates potential cash flow challenges impacting liquidity.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue59.29B55.54B50.41B60.41B49.36B48.14B
Gross Profit32.39B29.65B25.01B31.81B26.87B26.14B
EBITDA12.29B10.34B7.63B16.06B14.18B15.50B
Net Income5.09B3.58B1.61B7.90B8.28B9.84B
Balance Sheet
Total Assets0.0093.36B83.87B76.60B69.68B57.51B
Cash, Cash Equivalents and Short-Term Investments1.44B1.44B1.42B484.60M759.40M484.60M
Total Debt0.0027.64B25.77B20.15B17.77B14.82B
Total Liabilities-46.03B47.33B42.71B36.12B36.09B31.50B
Stockholders Equity46.03B44.73B41.11B40.38B33.51B25.98B
Cash Flow
Free Cash Flow0.00-393.50M-126.20M37.40M342.60M442.30M
Operating Cash Flow0.006.02B6.66B9.94B9.11B7.33B
Investing Cash Flow0.00-6.82B-8.22B-9.96B-9.14B-9.41B
Financing Cash Flow0.00392.80M2.50B-266.40M302.60M2.55B

Laurus Labs Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price970.00
Price Trends
50DMA
890.04
Positive
100DMA
833.67
Positive
200DMA
712.71
Positive
Market Momentum
MACD
22.13
Negative
RSI
73.70
Negative
STOCH
95.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LAURUSLABS, the sentiment is Positive. The current price of 970 is above the 20-day moving average (MA) of 900.33, above the 50-day MA of 890.04, and above the 200-day MA of 712.71, indicating a bullish trend. The MACD of 22.13 indicates Negative momentum. The RSI at 73.70 is Negative, neither overbought nor oversold. The STOCH value of 95.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LAURUSLABS.

Laurus Labs Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
₹318.91B41.400.94%-2.34%6.64%
₹485.71B95.390.13%25.83%421.20%
₹498.48B114.160.13%6.80%-75.66%
₹326.29B41.910.31%11.49%35.00%
₹300.83B83.5262.25%-0.32%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
₹522.88B69.690.14%10.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:LAURUSLABS
Laurus Labs Ltd.
961.50
470.67
95.89%
IN:BIOCON
Biocon Limited
377.00
61.27
19.41%
IN:GLAND
Gland Pharma Ltd.
1,903.55
267.94
16.38%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
1,843.25
154.10
9.12%
IN:IPCALAB
IPCA Laboratories Limited
1,288.40
-295.17
-18.64%
IN:SUVENPHAR
Suven Pharmaceuticals Ltd.
786.35
-529.15
-40.22%

Laurus Labs Ltd. Corporate Events

Laurus Labs Releases Q2 FY26 Results Conference Call Recording
Oct 23, 2025

Laurus Labs Ltd. announced the availability of the audio recording for their Q2 FY26 results conference call, which was held on October 23, 2025. This update is part of their regulatory compliance and transparency efforts, providing stakeholders with access to detailed financial discussions and company performance insights.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025